HP
KBIO

Harbourvest Partners’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Harbourvest Partners’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,201
Closed -$28K – 30
2015
Q2 		$28K Hold
7,201
– – 0.01% 22
2015
Q1 		$28K Sell
7,201
-6,250
-46% -$28K 0.02% 19
2014
Q4 		$186K Buy
+13,451
New +$192K 0.1% 25

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Harbourvest Partners's KBIO Position: Q3 2015 in Review

Harbourvest Partners sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q3 2015, closing a stake of 7,201 shares — an estimated $28K sold.

Harbourvest Partners first reported a position in KBIO in Q4 2014 and held it in 3 quarters. The position peaked at $186K in Q4 2014. 14 funds tracked by Wall St. Rank hold KBIO as of Q3 2015.

  • Harbourvest Partners reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q3 2015 after selling out during the quarter.
  • Harbourvest Partners sold 7,201 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2015, an estimated $28K.
  • Harbourvest Partners first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q4 2014 and held it in 3 quarters.
  • Harbourvest Partners's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $186K in Q4 2014.
  • 14 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2015.

Based on Harbourvest Partners's 13F filing for Q3 2015, filed 13 Nov 2015.